Evidence map›Paper›PMID 41858315›Full record

ReviewBlood vessels, thrombosis & hemostasis2026

A contemporary review of plasminogen activator inhibitor 1 in cardiovascular disease and broader disease state implications.

Mebeli Becerra, Neha Soogoor, Justin Vu, Jacob Wortley, Mohanakrishnan Sathyamoorthy

Abstract readReview
In one paragraph

Review in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mebeli BecerraDepartment of Medicine, Burnett School of Medicine at Texas Christian University, Fort Worth, TX.
Neha SoogoorDepartment of Medicine, Burnett School of Medicine at Texas Christian University, Fort Worth, TX.
Justin VuDepartment of Medicine, Burnett School of Medicine at Texas Christian University, Fort Worth, TX.
Jacob WortleyDepartment of Medicine, Burnett School of Medicine at Texas Christian University, Fort Worth, TX.
Mohanakrishnan SathyamoorthyDepartment of Medicine, Burnett School of Medicine at Texas Christian University, Fort Worth, TX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasminogen activator inhibitor 1 (PAI-1) has well-described roles in cardiovascular disease states including clinical thrombosis, atherosclerosis, arteriosclerosis, and myocardial infarction. However, an evolving plethora of research associates PAI-1 with numerous other disease processes including inflammation and infection, diabetes, metabolic syndrome, neurodegeneration, and cancer. Aside from disease processes, PAI-1 has also recently been shown to be a key biomarker for aging with effects on skeletal muscle repair, cardiovascular health, and cellular senescence. This review provides a timely and comprehensive update of PAI-1's role in the pathogenesis of a diverse array of human diseases.

Identifiers

PMID41858315
PMCPMC12996778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.